Who
Michel Vounatsos
Director
Company insider
Files Form 4 as: Director, Zai Lab; Director, Revvity; Chief Executive Officer, Biogen.
In numbers
- Trades disclosed
- 100
- Buys
- 5
- Sells
- 0
- Bought
- $2.8M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 2 May 2016
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —10,831 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,074 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,338 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —21,253 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —977 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,218 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —783 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —955 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —18,332 at $0.00 | filing |
| 6 May 2022filed 9 May 2022 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —610 at $0.00 | filing |
| 6 May 2022filed 9 May 2022 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —744 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,191 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code J | —8,909 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —6,191 at $0.00 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Michel Vounatsos; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.